Page 22 - Simon Hicks News Today

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

About ANGLE plc www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix ® system, and it enables a liquid biopsy (a simple b...

  PCI Pal is a leading provider of Software-as-a-Service ("SaaS") solutions that empower companies to take payments from their customers securely, adhere to strict industry governance, and remove their business from the significant risks posed by non-compliance and data loss.  Our products secure payments and data in any business communications environment including voice, chat, social, email, and contact centre.  We are integrated to, and resold by, some of the worlds leading business commu...

Press release content from Accesswire. The AP news staff was not involved in its creation. Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker February 18, 2021 GMT Parsortix system able to harvest difficult-to-detect mesenchymal CTCs Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast cancers GUILDFORD, SURREY / ACCESSWIRE / February 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-...

    IOG owns and operates a 50% stake in substantial low risk, high value gas reserves in the UK Southern North Sea. The Companys Core Project targets a gross 2P peak production rate of 140 MMcfe/d (c. 24,000 Boe/d) from gross 2P gas Reserves of 302 Bcfe¹ + 2C gas Contingent Resources of 108 Bcfe², via an efficient hub strategy. In addition to the independently verified 2P reserves at Blythe, Elgood, Southwark, Nailsworth and Elland and 2C Contingent Resources at Goddard, ...

Investegate announcements from Intercede Group PLC, CLN Conversion to Equity

Highlights · Raising up to £2million via £1.5million Placing and £500,000 Broker Option primarily to fund multiple work programmes focused on: o Evaluating late-stage appraisal/development projects that would rebalance existing portfolio of production and exploration assets o Improving recovery from existing onshore UK fields including potential workovers on WF2 and WF9 wells at the West Firsby field o Continuing technical analysis a...

About IOG:   IOG owns and operates a 50% stake in substantial low risk, high value gas reserves in the UK Southern North Sea. The Companys Core Project targets a gross 2P peak production rate of 140 MMcfe/d (c. 24,000 Boe/d) from gross 2P gas Reserves of 302 Bcfe¹ + 2C gas Contingent Resources of 108 Bcfe², via an efficient hub strategy. In addition to the independently verified 2P reserves at Blythe, Elgood, Southwark, Nailsworth and Elland and 2C Contingent Resources at G...

  Bigblu Broadband plc (AIM: BBB), is a leading provider of alternative super-fast and ultra-fast broadband solutions throughout Australia, the Nordics and significant parts of the UK. BBB delivers a portfolio of super-fast wireless broadband products for consumers and businesses unserved or underserved by fibre. The Group has a significant target market with 3m customers in the territories we operate in with speeds of under 4 Mbps.   High levels of recurring revenue, increa...

ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy Findings support ANGLEs plan for the growth of a new "pharma services" business area using the Parsortix system as a biomarker for cancer drug trials allowing longitu...